BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33440385)

  • 21. Type I interferons for induction of remission in ulcerative colitis.
    Seow CH; Benchimol EI; Griffiths AM; Steinhart AH
    Cochrane Database Syst Rev; 2008 Jul; (3):CD006790. PubMed ID: 18646167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Marshall JK; Thabane M; Steinhart AH; Newman JR; Anand A; Irvine EJ
    Cochrane Database Syst Rev; 2012 Nov; 11():CD004118. PubMed ID: 23152224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methotrexate for maintenance of remission in ulcerative colitis.
    Wang Y; MacDonald JK; Vandermeer B; Griffiths AM; El-Matary W
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD007560. PubMed ID: 26263042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis.
    Stremmel W; Merle U; Zahn A; Autschbach F; Hinz U; Ehehalt R
    Gut; 2005 Jul; 54(7):966-71. PubMed ID: 15951544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.
    Haifer C; Paramsothy S; Kaakoush NO; Saikal A; Ghaly S; Yang T; Luu LDW; Borody TJ; Leong RW
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):141-151. PubMed ID: 34863330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Probiotics for maintenance of remission in ulcerative colitis.
    Iheozor-Ejiofor Z; Kaur L; Gordon M; Baines PA; Sinopoulou V; Akobeng AK
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD007443. PubMed ID: 32128794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Sutherland L; Macdonald JK
    Cochrane Database Syst Rev; 2006 Apr; (2):CD000544. PubMed ID: 16625537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1).
    Fellermann K; Schiefke I; Rácz I; Derova J; Jonaitis L; Wehrum S; Nacak T; Greinwald R
    United European Gastroenterol J; 2020 Dec; 8(10):1186-1195. PubMed ID: 33028169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Sutherland L; Macdonald JK
    Cochrane Database Syst Rev; 2006 Apr; (2):CD000543. PubMed ID: 16625536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.
    Chande N; Wang Y; McDonald JW; MacDonald JK
    Cochrane Database Syst Rev; 2015 Aug; 8(8):CD006774. PubMed ID: 35658167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Probiotics for maintenance of remission in ulcerative colitis.
    Naidoo K; Gordon M; Fagbemi AO; Thomas AG; Akobeng AK
    Cochrane Database Syst Rev; 2011 Dec; (12):CD007443. PubMed ID: 22161412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cannabis for the treatment of ulcerative colitis.
    Kafil TS; Nguyen TM; MacDonald JK; Chande N
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012954. PubMed ID: 30406638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.
    Timmer A; Patton PH; Chande N; McDonald JW; MacDonald JK
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD000478. PubMed ID: 27192092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis.
    Cohen RD; Woseth DM; Thisted RA; Hanauer SB
    Am J Gastroenterol; 2000 May; 95(5):1263-76. PubMed ID: 10811338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.
    Prakash A; Markham A
    Drugs; 1999 Mar; 57(3):383-408. PubMed ID: 10193690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Murray A; Nguyen TM; Parker CE; Feagan BG; MacDonald JK
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD000544. PubMed ID: 32856298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclosporine A for induction of remission in severe ulcerative colitis.
    Shibolet O; Regushevskaya E; Brezis M; Soares-Weiser K
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004277. PubMed ID: 15674937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.
    Lawson MM; Thomas AG; Akobeng AK
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005112. PubMed ID: 16856078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.
    Timmer A; McDonald JW; Tsoulis DJ; Macdonald JK
    Cochrane Database Syst Rev; 2012 Sep; (9):CD000478. PubMed ID: 22972046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
    Rubin DT; Dotan I; DuVall A; Bouhnik Y; Radford-Smith G; Higgins PDR; Mishkin DS; Arrisi P; Scalori A; Oh YS; Tole S; Chai A; Chamberlain-James K; Lacey S; McBride J; Panés J;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):17-27. PubMed ID: 34798036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.